Jakob Loven, PhD

IV-formulated RNA Restoring Loss of Function of PGC1a and STMN2 in ALS Neurodegeneration. A Significant IV-formulated RNA Weapon in ALS Emerges. Join us at #BIO24 where we're leveraging the power of our proprietary IV—and SC-formulated RNA delivery platform with unprecedented precision to deliver therapeutic agents directly to the CNS, reaching #astrocytes, #microglia, and #neurons with unmatched efficiency. Our ALS target regulates PGC1a and STMN2, which are vital in mitochondrial dynamics and axonal integrity. Dysregulation of these pathways is a cornerstone of ALS pathology, leading to neurodegeneration, inflammation, and cognitive deficits. Further highlights: - Imagine showcasing dramatic improvements in neuromuscular function, evidenced by enhanced CMAP latencies and amplitudes – key indicators of neuromuscular health. Imagine the potential of BMD-001s in halting ALS progression and dramatically improving patients' lives. - With a significant reduction in NfL levels in the CSF, a promising biomarker of neurodegeneration, BMD-001s stands as a testament to our commitment to transforming patient lives. With our new external feasibility study partners, RNAi therapeutics is transforming the future of neurodegenerative disease treatment. #ALS, #RNAiTherapeutics, #Biorchestra, #Neurodegeneration, James Sabry, Roche, Felix Schumacher, The ALS Association, Manish Raisinghani, Daniel Roth, Annette Bak Asceneuron SA, Al Roker, Ferring Pharmaceuticals, Christian Mueller, Sanofi, Francisco Córdoba, Novartis, Juergen Reess, Amylyx Pharmaceuticals, Hans-Juergen Woerle, Servier, UCB, Pfizer, Paul Hudson, Wellington Management, John C. Reed, The Janssen Pharmaceutical Companies of Johnson & Johnson, Pierre Fabre Group, CSL, Brendan Nagle, Wells Fargo Corporate & Investment Banking, Murphy Gallagher, Leerink Partners LLC, Research Division, Leerink Partners, David Soria, Jefferies, n-Lorem Foundation, Endpoints News, STAT, Boston Globe Technology Branden JH (jin-hyeob) RYU, IL-SANG YOON, Fierce Biotech. Photo: Tennessee Titans legend Tim Shaw.

12

A toolbox rather than a tool, with unrivalled efficiency ….

12

RenBio is thrilled to announce that our most recent review , "Delivery of DNA-Based Therapeutics for Treatment of Chronic Diseases,” is out (https://lnkd.in/e8usgcgs)! Led by Research Associate Carleigh Sussman, it provides a comprehensive overview of gene therapy's evolution and its pivotal role in modern medicine. It delves into the promise of DNA-based medicines, particularly in managing chronic conditions more effectively. The review explores two key DNA-based gene therapies: adeno-associated virus (AAV)-based gene therapy and plasmid DNA (pDNA)-based gene therapy. It discusses how both have shown immense potential in clinical trials, offering robust and durable expression of therapeutic genes with fewer treatments compared to traditional approaches. Moreover, this review sheds light on the use of electroporation (EP) as a method for pDNA delivery. EP has emerged as a promising technique to enhance the efficacy and durability of pDNA-based therapies, paving the way for more efficient treatment strategies for chronic diseases.  #GeneTherapy #ChronicDiseases #ResearchInnovation

42

Navigating the Challenges of iPSC Differentiation: The Advantages of Tubular Bowl Centrifuges in Media Exchange In the rapidly evolving field of regenerative medicine, the cultivation of induced pluripotent stem cells (iPSCs) represents a cornerstone of therapeutic innovation. iPSCs hold unparalleled potential for disease modeling, drug discovery, and the development of cell therapies, owing to their ability to differentiate into any cell type. However, the translation of iPSC technology from bench to commercial bioproduction hinges on the development and implementation of scalable, efficient, and cell-friendly bioprocessing techniques. Here we introduce a novel approach to media exchanges, employing a tubular bowl centrifuge to address the critical requirements for media exchange during iPSC cultivation. https://lnkd.in/gZkzG2aY #aspenalert #biotech #bioprocess

1

🔬✨ Conference Wrap-Up: International Society for Extracellular Vesicles 2024✨🔬 As we reflect on an insightful week at the ISEV 2024, we at Mesenbio are invigorated by the vibrant discussions and groundbreaking research shared among the global community. 🌟 David Kuntin, CEO of Mesenbio, remarked on the collaborative spirit and forward momentum of the conference, noting, “This year's ISEV has been particularly inspiring with a palpable sense of positivity as more treatments progress towards clinical trials. It's encouraging to see new practical solutions emerging that will enhance our ability to translate basic research into real-world applications. This evolution of the field is a testament to the hard work and innovative thinking of our community." 🔬Paul Genever, CSO, shared his insights, saying, "This year's conference has truly underscored the complexity and potential of extracellular vesicles in biomedicine. As an academic, I'm particularly excited about the emerging evidence that links vesicle biology with fundamental cellular processes. This deepening understanding is not only fascinating but also critical as we design next-generation therapies that aim to exploit these natural biological systems for transformative health solutions." 🧬 Dave Mentlak, Senior Scientist, highlighted the technical sessions, stating, "The detailed discussions on the latest analytical techniques and their applications in diagnostics and therapeutics have provided valuable insights that will enhance our ongoing projects and research trajectory. I was particularly fascinated by the sessions on non-vesicular secreted particles, like matrimeres, and their role in tissue function. Understanding these interactions opens new avenues for our research." 🔍 Ryan Farley, Scientist I, expressed his enthusiasm about pace of innovation field’s optimism: "Connecting with peers and industry leaders who are equally passionate about the potential of extracellular vesicles has been incredibly inspiring. It has cemented the fact that I have joined a fast-moving and exciting field in which we can make a real difference." We are thankful to the organizers and all participants for an enriching experience. The insights gained here will undoubtedly fuel our mission to innovate and lead in the field of extracellular vesicle research. We're already looking forward to ISEV 2025! #ISEV2024 #Biotechnology #ExtracellularVesicles #Innovation #Science #Research #Mesenbio

31

New vinylsulfonyl piperazine handle for DCF16 E3 ligase targeting covalent degraders.

5

Investing in vision: Innovation in retinal therapeutics and the influence on venture capital investment https://lnkd.in/d2QHx_bH by Dr. Dmitrij Hristodorov, Tim Lohoff, Nanna Lüneborg, Geert-Jan Mulder, Simon J. Clark. Highlights: 1. The acquisition of Gyroscope by Novartis for up to $1.5 Billion in 2022, including an upfront payment of $800 million. It was a landmark deal for the founding investor, Syncona Limited, delivering an impressive ~$424 million upfront return. Other investors in Gyroscope, including Forbion, Sofinnova Investments and T. Rowe Price Associates enjoyed a quick return following their investment into the company in 2021. Regrettably, Novartis has recently announced that further development of GT005 has been stopped. In a press release, Novartis states that “this decision was based on a recommendation from the independent Data Monitoring Committee following an overall risk-benefit assessment of available data from the program studies, which concluded futility criteria had been met. Importantly, no new safety signals were identified” 2) Increasingly clinical-stage programs can be developed by biotech companies on a standalone basis, with increasingly larger financing rounds. Between 2004 and today, the average financing round has almost quadrupled from around $17 M in 2004 to around $63 M in 2022 and 2023 3) The likelihood of drug approval for ophthalmic drugs after a positive Phase 2 read-out is ~47% only and compares unfavorably to several other therapeutic areas. The availability of larger funds provided by VCs to run larger Phase 2 b and/or even pivotal Phase 3 studies will allow us to close this potential gap of innovation in the coming future 4) 9 out of the 15 largest financings were for gene therapy companies 5) The surge of investment has been paralleled by a growing appetite from pharma in the ophthalmology sector, highlighted by the most recent mega-deal, the acquisition of Iveric Bio, An Astellas Compan by Astellas for $5.9 billion. Pharma companies have become aware of the enormous impact and financial success they can generate, as showcased by blockbuster anti-VEGF drugs, such as Lucentis and Eylea

8

#ASCO24 (June 1st): 📢 If you are interested in the #Claudin (#CLDN) space, please check out my CLDN18.2 and CLDN4 summary. 📢Different therapeutics modalities with the potential to further improve efficacy, specifically ADC 📢Huge competition in the CLDN18.2 space, it is saturated #CLDN18.2 #ADC -IBI343 (Exatecan): 28% ORR in PDAC/BTC - AZD0901 (MMAE): 48% ORR; 4.8mo PFS; 11.8 mo OS in GC/GEJ #CLDN18.2 #monoclonal - Zolbetuximab + chemotherapy: 48% ORR; 11 mo PFS; 18 mo OS in GC/GEJ - Osemitamab + nivolumab+ chemotherapy: 68% ORR; 12.6 mo PFS in GC/GEJ - FG-M108 + chemotherapy: 80.6% ORR; 9.6 mo PFS in GC/GEJ #CLDN18.2 #bispecific - PM1032 (CLDN18.2/4-1BB): 20% ORR in GC/GEJ #CLDN18.2 #expression - No correlation with PD-L1, HER2, TIL density in GC - Highly expressed in small bowel adenoca #CLDN4 #bispecific -ASP1002 (CLDN4/CD137): Ph1 ongoing

127

3 Kommentare

Nextgen anti-CTLA-4 is essential for MSS CRC in a neoadjuvant setting!

9

1 Kommentar

PRESS RELEASE:  Alithea Bio ACQUIRES THE #TIMSTOF ULTRA FOR PIONEERING #IMMUNOPEPTIDOMICS RESEARCH.   Berlin, GERMANY, 25.04.2024 – Alithea Bio , a privately held biotech company in the realm of #immunopeptidomics and #peptide-based #immunotherapy has acquired a #timsTOFUltra and signed a partnership agreement with Bruker Corporation, a leading global developer and provider of #mass spectrometry solutions. The strategic partnership aims to advance the landscape of #immunopeptidomics mass #spectrometry in the characterization of #HLA peptides from pre-analytic enrichment techniques to CCS-leveraged #databases for these important classes of non-tryptic #peptides.  Alithea Bio will develop #proprietary methods using the revolutionary #TIMS-PASEF based polygon filtering methods exclusively available on the timsTOF platform, to achieve highly sensitive and reliable quantification of HLA peptides and neoepitopes. Fanny Giannou, the CEO of Alithea Bio Bio, expressed her enthusiasm about the #collaboration, stating, "This partnership underscores Alithea Bio 's position in the HLA #peptidomics domain and bolsters our commitment to pushing the boundaries of our technology for #diagnostic applications. Aligning forces with Bruker Corporation is a testament to our dedication to foster the global development and realization of safe and effective immunotherapies." Daniel Hornburg, Vice President for Biomarkers & Precision Medicine at Bruker Corporation, said “Bruker's #timsTOF Ultra is uniquely positioned to comprehensively map the ‘immunopeptidome’ combining highest #sensitivity, #precision, and #robustness with the unique polygon filtering, a trapped ion mobility enabled strategy that specifically selects #ions of interest leveraging the additional dimension of collision cross-section (CCS) molecular shape information. We are excited to #collaborate with Alithea Bio and support their differentiated #expertise in sample preparation and significantly improve the confidence of identification through CCS-enabled neoepitope databases.” Tim Fugmann, the CSO of Alithea Bio, added, "By harnessing the #sensitivity and #PASEF derived speed of Bruker Corporation’s timsTOF Ultra systems, we are set to achieving the profiling of complete #HLA peptidomes in single runs within this year. This ambitious #goal signifies a monumental stride forward, not only facilitating the #discovery of novel drug #targets but also furnishing indispensable safety information."   In the spirit of relentless #innovation, this #collaboration promises to usher in a new era for #Immunopeptidomics research.   About  Alithea Bio is a privately held biotech company with registered office in Freiburg, GERMANY. Alithea Bio is supporting Biopharma worldwide with #immunopeptidomics analysis and an extensive #HLA peptide database including more than 4.000 samples for #target #discovery, target #validation and #off-target toxicity prediction.

35

2 Kommentare

🚨Groundbreaking News from Gisens Biotech🚨 We’ve recently published our latest article that crystallizes our longstanding and unwavering mission: to revolutionize healthcare by bringing ultra-precise, affordable, and patient-centric diagnostics into every patient’s hands. Our novel graphene lab-on-a-chip (G-LOC), a unique biosensing solution leveraging #nanotechnology, #microfluidics, and #electronics, delivers over 95% accuracy when testing kidney function biomarkers (on par with lab-based analyzers) while being portable, easy to use, and patient-centric in its design. ⚠️Key Highlights: • Comprehensive Testing: The study included testing using human serum samples (CRM), at both healthy and renal failure levels, as well as human saliva samples. • UX Validation: During our UX testing, we proved that lay users obtain results comparable to trained chemists, showcasing the design and robustness of the technology, perfectly suited for at-home use by untrained patients. 🚀 A Major Breakthrough: This represents the first time in peer-reviewed, well-documented scientific history that a graphene biosensor is tested outside of the controlled environment of a lab, by lay users, with real complex samples, and without the need for complex or expensive equipment. A few years back, we sat with our early investors and made a promise to deliver “multiplex, accurate, fast, and patient-centric diagnostics,” and today we’re delivering on that promise: • Multiplex: Testing 4 different analytes with just one sample. • Accurate: Over 95% accuracy. • Fast: Approximately 7 minutes. • Patient-Centric: 100% of lay users in the study said that G-LOC would be suitable for at-home use, with results comparable to trained chemists. We also wish to thank folks who volunteered to get tested with GLOC, on the side, while we were stealthily conducting this study. Thank you Federico Marque, George Panagiotakopoulos, Caroline Winnett, and many more… Congrats Gisens Biotech team, Esteban Piccinini Joaquín Diforti Omar Azzaroni Waldemar Marmisolle Luis Pierpauli GRIDX Berkeley SkyDeck Creative Destruction Lab Universidad Nacional de La Plata Soft Matter Laboratory Life Sciences Entrepreneurship Center Darren Cooke Chon Tang Read the full article here

30

3 Kommentare

It's increasingly difficult for biotech companies to secure funding. As a result, biotechs are looking for new ways to communicate their value to investors. Development pipelines are traditionally seen as tools to gain regulatory approval for novel drugs, but this isn't the only role they can play. Pipelines can also be a valuable tool for securing investment. This is because a solid pipeline highlights your understanding of the development process and demonstrates how you aim to overcome certain challenges along the way. In an industry where 90% of drug candidates fail, this is an excellent way to provide investors with some confidence and peace of mind. #Funding #Biotech #VentureCapital #BusinessStrategies

18

1 Kommentar

MIRA Pharmaceuticals Announces Ketamir-2 Shows Promising Safety Profile Compared to Traditional Ketamine Our novel oral ketamine analog, Ketamir-2, has demonstrated a significantly improved safety profile in preclinical studies conducted by Biotrial Unlike traditional ketamine, Ketamir-2 does not induce hyper-locomotor activity or schizophrenia-like behaviors, potentially offering a safer option for mental health treatments We are on track to submit an Investigational New Drug (IND) application to the FDA by the end of this year, paving the way for groundbreaking advancements in patient care. Read more about our latest study: https://lnkd.in/eQTG2-vx #MIRAPharmaceuticals #Ketamir2 #MentalHealth #Neuroscience #Pharma #Biotech #Innovation #PatientCare #Schizophrenia #Mira #IND #Fda #Depression #Ptsd #CancerPain #NeuropathicPain #TRD

43

1 Kommentar

Here we look at some quotes from the recent Investment Reports article "The Many Faces of Oncology" (https://lnkd.in/gsYX84RB) that highlight why iPSirius is currently an attractive company for investing in: "The field of oncology continues to attract substantial investment..." This quote underscores the attractiveness of the oncology sector for investors, implying potential opportunities for companies like iPSirius operating within this field. "Innovative approaches to cancer treatment are gaining traction..." This suggests that investors are likely interested in companies like iPSirius that are pioneering innovative approaches to cancer treatment, indicating growth potential and market demand. "Companies with promising pipeline candidates are commanding attention..." iPSirius, with its innovative therapeutic product IPVAC1.0 targeting non-small cell lung cancer (NSCLC), aligns with this description, potentially making it an attractive prospect for investors seeking promising pipeline candidates. "Investors are increasingly looking for opportunities in personalized medicine..." As iPSirius aims to leverage induced pluripotent stem cells (iPSCs) for personalized cancer therapy, this quote suggests that the company's focus on personalized medicine could appeal to investors seeking opportunities in this space. "Partnerships and collaborations are becoming pivotal for success..." iPSirius' strong working relationship with organizations like Cell and Gene Therapy Catapult and the Scottish National Blood Transfusion Service SNBTS demonstrate its proactive approach to forming strategic partnerships, which could enhance its attractiveness to investors interested in companies with strong collaborative networks. iPSirius' activity aligns with current trends and investor interests in the oncology sector, personalized medicine, innovation, and strategic collaborations. See more at www.iPSirius.com #iPSirius #oncotherapy #cancer #immunotherapy #investinbiotech

3

Sharing an interesting article on Delphia Therapeutics new area of cancer biology, activation lethality.  Delphia integrates tumor genetics, novel functional genomic approaches, and studies of inhibitor drug resistance to identify targets that drive activation lethality. Through its activation lethality platform, Delphia is advancing a pipeline of first-in-class cancer medicines that aim to better control oncogenic pathways. Delphia completed a $67 million Series A financing led by premier early life sciences investors including GV (Google Ventures), Nextech Invest Ltd , Polaris Innovations Fund and Alexandria Venture Investments. Looking for commercialization consulting for your Phase 1b - 3 emerging biotech? Check out my site www.bridge1.net. Let me help you manage the roadblocks to commercialization success. #commercialization #oncology #cancer #cancertreatment #lethality #tumorgenetics https://lnkd.in/gQfiBXKd

7